Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Public ClinicalTrials.gov record NCT04541225. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Study identification
- NCT ID
- NCT04541225
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Enrollment
- 74 participants
Conditions and interventions
Conditions
- Advanced Breast Cancer
- Advanced Breast Carcinoma
- Breast Cancer
- Breast Carcinoma
- Breast Tumor
- Cancer of Breast
- Cancer of Prostate
- Cancer of the Breast
- Cancer of the Prostate
- Castrate Resistant Prostate Cancer
- Castration Resistant Prostatic Neoplasms
- Castration-resistant Prostate Cancer
- Glial Cell Tumors
- Glioblastoma
- Glioma
- Glioma, Malignant
- Glioma, Mixed
- Malignant Tumor of Breast
- Metastatic Breast Cancer
- Metastatic Breast Carcinoma
- Prostate Cancer
- Prostate Neoplasm
- Prostatic Cancer
- Recurrent Glioblastoma
Interventions
- NUV-422 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 7, 2020
- Primary completion
- Aug 30, 2022
- Completion
- Aug 30, 2022
- Last update posted
- Jul 13, 2023
2020 – 2022
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates | Tucson | Arizona | 85711 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | — |
| Prisma Health Cancer Institute | Greenville | South Carolina | 29605 | — |
| Texas Oncology P.A. Austin | Austin | Texas | 78705 | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology | Tyler | Texas | 75702 | — |
| University of Utah Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04541225, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 13, 2023 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04541225 live on ClinicalTrials.gov.